Impact of Frontline Immune Checkpoint Inhibitors on Therapy for Relapsed/Refractory Hodgkin Lymphoma

Presented by:
Ryan C. Lynch
Search for other papers by Ryan C. Lynch in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 23: Issue Supplement
Online Publication Date:
27 May 2025
DOI:
https://doi.org/10.6004/jnccn.2025.5007
Restricted access

The integration of immune checkpoint inhibitors into frontline therapy for classical Hodgkin lymphoma (cHL) is reshaping the treatment landscape. As PD-1 blockade moves earlier in care, it alters transplant strategy, drug sequencing, and the role of established agents such as brentuximab vedotin. This article summarizes updates presented at the NCCN 2025 Annual Conference, focusing on how first-line PD-1 inhibition influences management in relapsed or refractory cHL and creates new questions around optimal treatment sequencing.

Disclosures: Dr. Lynch has disclosed receiving consulting fees from AbbVie Inc., ADC Therapeutics, and Janssen Pharmaceutica Products; receiving grant/research support from Allogene Therapeutics, Inc., Cyteir Therapeutics, Genentech, Inc., Incyte Corporation, Janssen Pharmaceutica Products, Pfizer Inc., and RAPT Therapeutics; and receiving honoraria from Merck & Co., Inc.

Correspondence: Ryan C. Lynch, MD, Fred Hutchinson Cancer Center, 825 Eastlake Avenue East, LG-650, Seattle, WA 98109. Email: rclynch@uw.edu
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Herrera AF, LeBlanc M, Castellino SM, et al. Nivolumab+AVD in advanced-stage classic Hodgkin’s lymphoma. N Engl J Med 2024;391:1379–1389.

  • 2.

    Hoppe RT, Advani RH, Ambinder RF, et al. NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma. Version 2.2025. Accessed February 16, 2025. To view the most recent version, visit https://www.nccn.org

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Brockelmann PJ, Buhnen I, Meissner J, et al. Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group phase II NIVAHL trial. J Clin Oncol 2023;41:1193–1199.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Ansell SM, Bröckelmann PJ, von Keudell G, et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study. Blood Adv 2023;7:6266–6274.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Armand P, Zinzani PL, Lee HJ, et al. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma. Blood 2023;142:878–886.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Mei M, Chen L, Godfrey J, et al. Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade. Blood 2023;142:1359–1370.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Nie J, Wang C, Liu Y, et al. Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed/refractory classical Hodgkin lymphoma. J Clin Oncol 2019;37:1479–1489.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Wang C, Liu Y, Dong L, et al. Efficacy of decitabine plus anti-PD-1 camrelizumab in patients with Hodgkin lymphoma who progressed or relapsed after PD-1 blockade monotherapy. Clin Cancer Res 2021;27:2782–2791.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Ramos CA, Grover NS, Beaven AW, et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2020;38:3794–3804.

Copyright:
Copyright © 2025 by the National Comprehensive Cancer Network 2025
Article Category:
Abstract
Print Publication Date:
01 May 2025
Online Publication Date:
27 May 2025

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1912 1912 1912
PDF Downloads 77 77 77
EPUB Downloads 0 0 0